Riskpilot← Back to searchSign inGet full accessMEDISTIM NORGE AS
ASActiveOrg 937729111Økernveien 94, 0579 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 198514 employees
Revenue 2024
NOK 88,5M
+9% vs 2023
EBITDA margin
16.3%
+11% vs 2023
Equity ratio
42.0%
Financial strength
Net profit 2024
NOK 11,7M
+7% vs 2023
| Revenue | NOK 88,5M | +9% |
| EBITDA | NOK 14,4M | +11% |
| Net profit | NOK 11,7M | +7% |
| Total assets | NOK 43,5M | +7% |
| Equity | NOK 18,3M | -1% |
| Employees | 14 | — |
Legal name
MEDISTIM NORGE AS
Org number
937729111
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. oktober 1985
Share capital
NOK 151 500
Employees
14 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Økernveien 94, 0579 Oslo
Phone
+4723035250
Email
medistim@medistim.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 69 113 | 73 779 | 76 923 | 80 974 | 88 523 |
| Staff expenses | −12 827 | −13 715 | −13 462 | −14 195 | −16 060 |
| EBITDA | 11 543 | 13 629 | 12 823 | 12 998 | 14 413 |
| Depreciation & amort. | −285 | −332 | −349 | −647 | −613 |
| EBIT | 11 258 | 13 297 | 12 474 | 12 351 | 13 800 |
| Net financials | 117 | 604 | 974 | 1 309 | 1 143 |
| Profit before tax | 11 375 | 13 901 | 13 448 | 13 660 | 14 943 |
| Tax | 2 402 | 2 966 | 2 756 | 2 715 | 3 197 |
| Net profit | 8 973 | 10 935 | 10 692 | 10 945 | 11 746 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 42 689 | 44 956 | 41 333 | 40 544 | 43 468 |
| Equity | 31 942 | 18 877 | 18 569 | 18 513 | 18 259 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 747 | 26 079 | 22 764 | 22 031 | 25 209 |
| Total debt | 10 747 | 26 079 | 22 764 | 22 031 | 25 209 |
EBITDA margin
16.3%
This company
15.8%
Market median
+3% vs market
20202024
Equity ratio
42.0%
This company
38.2%
Market median
+10% vs market
20202024
Return on equity
64.3%
This company
18.4%
Market median
+249% vs market
20202024
Net profit margin
13.3%
This company
8.1%
Market median
+64% vs market
20202024
Asset turnover
2.04×
This company
1.12×
Market median
+82% vs market
20202024
Debt / equity
1.38×
This company
0.62×
Market median
-123% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ES Deputy Member | Deputy Member | 2009 |
OR Chief Executive Officer | Chief Executive Officer | 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2009 | |
| Board of Directors | 2009 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Medistim Asa
MEDISTIM NORGE AS Board members of MEDISTIM NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Swensen | Deputy Member | 0 companies |
| Ole-Jørgen Robsrud | Chief Executive Officer | 0 companies |
| Kari Eian Krogstad | Chairman | 0 companies |
| Thomas Jakobsen | Board of Directors | 0 companies |